

2022-2026 US Cancer Diagnostics Market Opportunities for Major Tumor Markers-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/2DF4B2EC8C86EN.html

Date: January 2022 Pages: 0 Price: US\$ 3,500.00 (Single User License) ID: 2DF4B2EC8C86EN

# **Abstracts**

LeadingMarketResearch.com's new report is a study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years.

The report is available by section, and can be customized to specific information needs and budget.

The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

# Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer



therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

U.S. Market Overview

Five-year test volume and sales projections.

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Estimated universe of laboratories performing cancer diagnostic testing.

Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

**Biochemical Markers** 

Oncogenes

**Growth Factors** 

Hormones

**Colony Stimulating Factors** 



#### Lymphokines

Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

#### Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test.

Five-year test volume and sales forecasts for major tumor markers by market segment, including:

Hospitals

Commercial/Private Laboratories

**Physician Offices/Group Practices** 

Cancer Clinics

#### Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

#### **Technology Assessment**

2022-2026 US Cancer Diagnostics Market Opportunities for Major Tumor Markers-Competitive Shares and Growth Str...



Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

**Competitive Strategies** 

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujirebio, Grifols, Hologic, Leica Biosystems, Ortho-Clinical Diagnostics, PerkinElmer, Qiagen, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher, Wako and others.



# Contents

## I. INTRODUCTION

## II. WORLDWIDE MARKET OVERVIEW

## **III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- **D.** Auxiliary Products

## **IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

## **V. ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

#### **VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

#### VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
- 1. Breast Cancer
- 2. Lung Cancer
- 3. Colon and Rectum Cancer
- 4. Prostate Cancer

2022-2026 US Cancer Diagnostics Market Opportunities for Major Tumor Markers-Competitive Shares and Growth Str...



- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer
- B. Major Current and Emerging Cancer Diagnostic Tests
  - 1. Introduction
  - 2. Tumor Marker Classification
  - 3. ACTH
  - 4. Alpha-Fetoprotein (AFP)
  - 5. Beta-2 Microglobulin
  - 6. CA 15-3/27.29
  - 7. CA 19-9
  - 8. CA-125
  - 9. Calcitonin
  - 10. Carcinoembrionic Antigen (CEA)
  - 11. Estrogen and Progesterone Receptors
  - 12. Ferritin
  - 13. Gastrin
  - 14. Human Chorionic Gonadotropin (HCG)
  - 15. Insulin
  - 16. NSE
  - 17. Occult Blood
  - 18. PAP Smear/HPV
  - 19. Prostatic Acid Phosphatase (PAP)
  - 20. Prostate-Specific Antigen (PSA)
  - 21. Squamous Cell Carcinoma Antigen (SCC)
  - 22. T and B Lymphocytes
  - 23. TdT
  - 24. Thyroglobulin
  - 25. Tissue Polypeptide Antigen (TPA)
  - 26. Biochemical Tumor Markers
  - 27. Oncogenes
    - Abl/abl-bcr
    - AIB1
    - BCL-2





BRCA1 **CD44** C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src and others 28. Polypeptide Growth Factors **Basic Fibroblast Growth Factor** Beta-TGF Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines Alpha-Interferon **B Cell Growth Factors B** Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains



33. Emerging Tumor Markers N-Acetylglucosamine Actin Alpha-Actin **Antineuronal Antibodies** 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B **Cluster 1 Antigen** Cluster-5/5A Antigen CTA **CU18 DR-70** DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2



Human Carcinoma Antigen **HPA** HSP27 Intermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein Neurofilaments** Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opioid Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret



Selectin Sialic Acid Sialyl SSEA-1/SLX SN10 Somatostatin TA-90 TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen and others

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
  - 1. Monoclonal and Polyclonal Antibodies
  - 2. Immunoassays
  - 3. Molecular Diagnostics
  - 4. Chromosome Analysis
    - a. Chronic Myelogenous Leukemia (CML)
    - b. Acute Myeloid Leukemia (AML)
    - c. Acute Lymphoblastic Leukemia (ALL)
    - d. Malignant Lymphomas Lymphoid Malignancies
    - e. Chronic Lymphocytic Leukemia (CLL)
    - f. Solid Cancers
    - g. Chromosomal Translocation and Oncogenes
  - 5. Artificial Intelligence
  - 6. Flow Cytometry
  - 7. Two Dimensional Gel Electrophoresis (2-DGE)
  - 8. Biosensors
  - 9. Competing/Complementing Technologies
- E. Personal Testing

# VIII. COUNTRY ANALYSIS

- A. Executive Summary
- B. Business Environment



- C. Market Structure
- D. Market Dynamics, Trends, Size and Growth Volume Forecasts by Test and Market Segment Sales Forecasts by Test and Market Segment Major Supplier Sales and Market Shares

## **IX. COMPETITIVE PROFILES**

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott Affymetrix Beckman Coulter/Danaher **Becton Dickinson** bioMerieux **Bio-Rad** Cepheid DiaSorin **Eiken Chemical** Elitech Group Enzo Biochem Fujirebio Grifols Hologic Leica Biosystems **Ortho-Clinical Diagnostics** PerkinElmer Qiagen Roche **Siemens Healthineers** Takara Bio Thermo Fisher Wako and others.



## I would like to order

Product name: 2022-2026 US Cancer Diagnostics Market Opportunities for Major Tumor Markers-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: https://marketpublishers.com/r/2DF4B2EC8C86EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/2DF4B2EC8C86EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970